Neuralstem’s lead drug crumbles in PhII, adding to a litany of failures for depression drugs and blasting shares
Neuralstem $CUR says its Phase II study of the experimental depression drug NSI-189 — its lead therapy in the pipeline — failed to hit the primary endpoint, adding another flop to a field that has been stigmatized by regular failures and eviscerating the biotech’s stock.
The drug did not hit a statistically significant goal for reducing symptoms of depression based on the well known MADRS test. A secondary endpoint based on the Hamilton Depression Rating Scale was also missed, though the company noted it was “directionally positive.” A second secondary for a patient questionnaire did achieve statistical significance, though barely, with a p-value of 0.044.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.